Legal status · United States
Is Rusfertide legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
Yes. Rusfertide is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 7 human studies are cited on its profile.
Rusfertide in the United States at a glance
| Classification | FDA-approved, prescription only |
|---|---|
| Note | Mimrylo, NDA 220605, approved 28 August 2026; Drugs@FDA marketing status Prescription. Held by Takeda Pharmaceuticals USA. |
| FDA approval status | FDA approved 28 August 2026 (Mimrylo, NDA 220605, new molecular entity) for the treatment of erythrocytosis in adults with polycythaemia vera. Once-weekly subcutaneous injection, 9.5 to 54 mg vials. |
| Human studies cited | 7 of 9 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Rusfertide profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
FDA has approved Rusfertide for at least one labeled indication, so a pharmaceutical-grade product exists in the United States and is dispensed on prescription.
- 02
Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.
- 03
Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.
What Rusfertide is
An 18 residue cyclic peptide that mimics the iron hormone hepcidin, approved by the FDA on 28 August 2026 for erythrocytosis in adults with polycythaemia vera. In the 293 person VERIFY trial, 76.9 percent on rusfertide against 32.9 percent on placebo avoided qualifying for a phlebotomy between weeks 20 and 32.
Rusfertide is a synthetic, lipidated, disulfide-bridged 18 amino acid peptide that copies the action of hepcidin, the liver hormone that controls how much iron reaches the bloodstream. In polycythaemia vera the bone marrow makes too many red cells; the standard control is repeated phlebotomy, which leaves patients iron deficient.
Mechanism: Hepcidin binds ferroportin, the only known cellular iron exporter, and causes it to be internalised and degraded. That traps iron inside gut cells and macrophages and lowers serum iron, so the marrow has less iron to build haemoglobin.
Regulatory history: FDA approved 28 August 2026 (Mimrylo, NDA 220605, new molecular entity) for the treatment of erythrocytosis in adults with polycythaemia vera. Once-weekly subcutaneous injection, 9.5 to 54 mg vials.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Rusfertide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Rusfertide in other countries
Frequently asked questions
Is Rusfertide legal in the United States?
Yes. Rusfertide is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 7 human studies are cited on its profile. Note: Mimrylo, NDA 220605, approved 28 August 2026; Drugs@FDA marketing status Prescription. Held by Takeda Pharmaceuticals USA.
Can I buy Rusfertide in the United States?
Only with a prescription. Rusfertide is classified as "FDA-approved, prescription only" in the United States, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection. Note: Mimrylo, NDA 220605, approved 28 August 2026; Drugs@FDA marketing status Prescription. Held by Takeda Pharmaceuticals USA.
Is Rusfertide FDA approved?
Yes. FDA status: FDA approved 28 August 2026 (Mimrylo, NDA 220605, new molecular entity) for the treatment of erythrocytosis in adults with polycythaemia vera. Once-weekly subcutaneous injection, 9.5 to 54 mg vials.. Current US classification: "FDA-approved, prescription only". On the evidence, 7 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Rusfertide live on its compound profile.
Rusfertide profileThis page is general information about the regulatory status of Rusfertide in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.